2025 Volume: 01 Issue: 07 www.ijrpa.com ISSN 2456-9995 **Review Article**

International Journal Research Publication Analysis

Page: 01-12

NANOPARTICLES DRUG DELIVERY SYSTEMS THE MAGIC BULLET FOR THE TREATMENT OF CHRONIC PULMONARY DISEASES.

***Pooja Kharosekar P**

Department of pharmaceutics , shivlingeshwar college of pharmacy.

Article Received: 10 November 2025
Article Revised: 30 November 2025
Published on: 20 December 2025

***Corresponding Author: Pooja Kharosekar P**
Department of pharmaceutics, shivlingeshwar college of pharmacy.
DOI: https://doi-doi.org/101555/ijrpa.7621

ABSTRACT

Chronic pulmonary diseases, encompassing conditions such as chronic obstructive pulmonary disease (COPD). Pose significant challenges in their treatment due to the complex nature of the lungs and the need for targeted medication delivery. Nanoparticles face challenges for targeted and controlled drug release within the lungs. Chronic lung disease includes a variety of persistent ung disordersr such as asthma, chronic obstructive pulmonary disease (COPD). Cys tic fibrosis, tuberculosis, idiopathic pulmonary fibrosis CIPF)C and lung cancer. Nanoparticle-based drugs in the treatment of respiratory disorders, including both basic and clinical studies. The nanopartlcle' s physicochemical properties can accomplish targeted therapeutic delivery. Based on their surface, size, density, and physical-chemical properties, nanopartlcles have dernonstrated enhanced pharmacoklnetlcs of actlves, acnevlng the spotlight In the delivery research neld. In this revtewr the authors have highlighted dlfferent nanopartlcle-based therapeutic delivery approaches to treat chronic pulmonary diseases along with the preparation techniquese

KEYWORDS: Chronic Lung Disease, Pulmonary Delivery, Nanoparticles, Lungs, Toxicity, Inhalation.

INTRODUCTION

Chronic pulmonary diseases, including Chronic: Obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF), cystic fibrosis (CF) , asthma, and lung cancers, represent a significant global health burden, affecting millions of individuals. Traditional pharmacotherapeutic approaches, such as bronchodilators and corticosteroids, often fail to provide satisfactory outcomes in managing these conditions. This inadequacy has led to the exploration of innovative treatment modalities, particularly nanoparticle-based drug delivery systems, which are increasingly recognized as potential "magic bullets" for targeted therapy in chronic pulmonary diseases.

The Concept of the "Magic Bullet '

According to the World Health Organization (WHO), respiratory diseases caused the deaths of at least 9 million people worldwide and resulted in numerous disabilities inTheso diseases accounted for approximately 15% of all deathsLowerrespiratory infections, pneumonia. bronchitis, tuberculosisr pharyngitis, laryngitis, and thecommon cold, as well as obstructive lung disorders, such as asthma. chronic obstructivepulmonary disease (COPD)r and lung cancer, are among the most prevalent respiratorydiseases. The main causes of respiratory diseases are air pollution, genetic attributes, andinfections caused by viruses and bacteria The lower respiratory airways could easily beinfected by airborne diseases and infections, influencing the lower airways and leading toacute respiratory infections.

The development of novel nanoparticle-based drug delivery systems, capable of targeting specific cells such as lung epithelial cells and macrophages while minimizing sys temic side effects is curren tly underway, has received special attention. These systems use nanoparticles, which are tiny particles ranging in size from 1 to 100 nanometres, to encapsulate and deliver drugs directly to affected areas of the lungs. By modifying the surface properties. surface properties of nanoparticles, researchers can improve their ability to selectively bind to specific cell types. Types in the lungs, thereby improving drug delivery efficiency and reducing side effects. Offtarget use. Addition, nanoparticle-based drug delivery systems can protect drugs from degradation and improve. stability, thereby ensuring sustained drug release and prolonging the therapeutic effect.



Flg no.1: Anatomy & Physiology of Respiratory System

Concept of Magic Bullet: The magic bullet concept is the basis for targeted drug delivery, which is a system that delivers drugs to specific areas of the body.

The magic bullet concept has led to the development of nanomedicine, which uses nanometer-sized devices to deliver drugs.

The magic bullet concept has been applied to treat cancer, neurological disorders, and cardiovascular ailments.

The magic bullet concept has led to the development of Salvarsan, the first effective drug for syphilis. Ehrlich and his team went on to develop the first pharmaceutical 'magic bullet', arsphenamine (Salvarsan®), which specifically targeted the bacterium Treponema pallidum, the causative organism of syphilis, without affecting normal host cells.One hundred years ago, Paul Ehrlich, the founder of chemotherapy, received the Nobel Prize for Physiology or Medicine. His postulate of creating 'magic bullets' for use in the fight against human diseases inspired generations of scientists to devise powerful molecular cancer therapeutics.kills specific bacteria inside the body without harming the body. is a chemical treatment that kills specific bacteria inside.

Nanoparticle In Drug Delivery System: Nanoparticles in drug delivery systems are very small particles, typically in the size range of 1 to 100 nanometres, designed to deliver therapeutic agents (such as drugs or genes) to specific cells, tissues, or organs in the body. The field of nanomedicine is the use of the unique properties of nanoparticles to improve the effectiveness and reduce side effects of various drugs. Nanomedicine and Nano delivery systems are relatively new but rapidly evolving sciences in which nanoscale materials can serve as diagnostic tools or deliver therapeutic agents to specific target sites in a controlled manner used to. Nanotechnology offers many advantages in the treatment of chronic human diseases through site-specific, targeted, and precise drug delivery. Nanoparticles are distinguished by their high stability, high specificity, high drug delivery capacity, controlled release capability, possibility of use in various drug delivery modes, and ability to transport both hydrophilic and hydrophobic properties. It can offer significant advantages over traditional drug delivery mechanisms. Molecules can be encapsulated within the nanoparticle spheres or attached to the surface. Once at the target site, the drug cargo is released from the nanoparticle through diffusion, swelling, erosion, or degradation. Active systems are also possible, e.g., Releasing drugs in response to external energy input.

NANOPARTICLES FOR BIOMEDICAL APPLICATIONS: Nanotechnology has the potential to revolutionize the field ofchemotherapy Nanoscaleplatforms aim to increase treatment efficacy and localize drugdelivery, resulting in reduced dosage, fewer systemic side effects,controlling biodistribution, modulating pharmacokinetics (releasekinetics and mechanism), and finally improving patient compliance Nano-architectures could be used toencapsulate different drugs, especially hydrophobic drugs.Nanoparticles can be thought of as tiny packages that containdrugs and can be delivered to specific locations in the body.

The major organic-based platforms for nanotechnology includecarbon nanodiamonds, nanotubes, graphene, graphene oxide,fullerenes, dendrimers, polymeric particles, solid lipid hybridnanoparticles, liposomes (most popular), pyrosomes,nanoemulsions, and graphene/carbon quantum dots (QDs). Inorganic-based drugdelivery systems comprise metal and metal oxide nanoparticles(especially gold for diagnosis and magnetic nanoparticles),metallic quantum dots, and porous materials.

APPLICATIONS IN CHRONIC PULMONARY DISEASES

 Targeted Delivery: Nanoparticles can be modified to specifically target the lungs or even specific cells
within the lungs (e.g., alveolar macrophages), leading to a more efficient treatment.
 Improved Bioavailability: The small size of nanoparticles allows them to penetrate biological barriers,
ensuring higher bioavailability of the drug at the site of action.
 Controlled Release: Nanoparticles can be engineered to release the drug over an extended period, reducing
the frequency of administration and improving patient compliance.
 Reduced Systemic Side Effects: Because of their targeted delivery, nanoparticles minimize exposure to
non-target tissues, thereby reducing side effects and toxicity.
 Enhanced Drug Stability: Nanoparticles can protect drugs from degradation in the body, increasing the
stability of sensitive biologic drugs or peptides.

Pulmonary Disease: Chronic respiratory diseases are long-term health conditions that affect a person's ability to breathe.
condition makes it difficult for the lungs to get enough air, which can cause symptoms such as shortness of
breath, coughing, and wheezing. Common examples of chronic respiratory diseases include asthma, chronic
obstructive pulmonary disease (COPD), and bronchitis. These conditions often require ongoing medical care
and can affect a person's quality of life.

Fundamentals of Nanoparticle-Based Drug Delivery System: Nanoparticle-based drug delivery systems (NDDS) represent a cutting-edge approach in pharmaceutical technology, utilizing engineered particles on the nanoscale (typically between 1 and 1000 nanometers) to deliver therapeutic agents in a controlled and targeted manner. The primary goal of NDDS is to enhance the pharmacokinetics, bioavailability, and therapeutic efficacy of drugs, while reducing side effects.

Advantages of Nanoparticle – Based Drug Delivery Systems: The application of nanoparticles in drug delivery offers several significant advantages, particularly in treating chronic pulmonary diseases:

 Enhanced Drug Solubility and Stability: Many drugs, especially those used in pulmonary therapy, have poor solubility. Nanoparticles can improve the solubility and stability of these drugs, ensuring more effective treatment.

Targeted and Controlled Drug Release: Nanoparticles enable the controlled release of drugs over extended periods, providing sustained therapeutic effects with fewer side effects.

Disadvantages of Nanoparticle-Based drug delivery systems:

1.Nanoparticles can be toxic to the body, especially to organs like the liver and lungs. They can also cause oxidative stress, which can damage DNA, proteins, and lipids.

2.Hypersensitivity reaction Nanoparticles can trigger hypersensitivity reactions by activating the immune

3.Regulatory challengesNew nanomedicines must undergo strict regulatory approval, which can slow down

4.CostThe development and production of nanoparticles can be expensive, which could limit theirs





Nanoparticles used for the treatment of respiratory disorders: several types of nanoparticles drug have been used for the treatment of different respiratory disorders .

Carbon-based nanomaterials: Carbon-based materials play important roles in theadvancement of material science, including a) traditionalindustrial carbon, such as activated carbon,b) new industrialcarbon, such as carbon fibers, and c) new carbon nanomaterials,such as graphene and carbon nanotubes. Primary investigation anduses of carbon-based materials are general in the interdisciplinaryfields, although macroscopic carbon material lacks a suitable bandgap, making it problematic to act as an efficient fluorescent material.



COPD: Chronic obstructive pulmonary disease (COPD) is a progressive chronic inflammatory lung disease characterized by persistent airflow limitation. The term "obstructive" in COPD refers to airflow restriction due to partial or complete obstruction of the airway. COPD is a multifactorial disease that is both preventable and treatable. It is currently the fourth leading cause of death worldwide and is predicted to become the third leading cause of death by 2020. Globally, the burden of the disease is expected to increase in the coming decades due to the continued burden of COPD risk factors and an aging population. Distinct symptoms commonly reported by COPD patients include coughing, sputum production, wheezing, and shortness of breath. However, the impact of symptoms on an individual patient's activities of daily living depends on many factors, including disease severity and comorbidities. Exacerbations of COPD are associated with increased upper and lower respiratory tract disease and systemic inflammation. Because it is difficult to perform a bronchial biopsy during an exacerbation to severe COPD in patients with moderate disease, there is little information about the nature of inflammatory changes in the airways, especially when examined near the exacerbation. In stable COPD,





Information of Magic Bullet: The term "magic bullet" was first introduced by Paul Ehrlich in 1907, referring to a therapeutic agent that can selectively target disease-causing agents without harming healthy tissues. This concept has evolved over theyears, particularly in the context of cancer therapy, but it remains relevant in the development of novel treatments for chronic pulmonary diseases.

Advantages of Magic Bullet: Targeted delivery

The "magic bullet" theory aims to deliver medicine to a specific target in the body while avoiding healthy tissues.

Reduced side effects

The "magic bullet" theory can reduce the amount of drug needed for therapeutic effect, which can reduce side effects.

Improved therapeutic efficacy

The "magic bullet" theory can improve the therapeutic efficacy of drugs by targeting specific organelles or cells.

Nanomedicine

The "magic bullet" theory has led to the development of nanomedicine, which uses nanometer-sized devices to deliver drugs.

Controlled drug release

Nanoparticles can provide controlled drug release, which can improve therapeutic levels and reduce systemic toxicity.

Improved solubility, stability, and degradation

Vesicular carrier systems can improve the solubility, stability, and rapid degradation of drug molecules.

Disadvantages of Magic Bullet: Antimicrobial resistance

The magic bullet approach has led to an increase in antimicrobial resistance (AMR) across all pathogens.

Treatment resistance

The first magic bullet drugs, such as arsphenamide, were not perfect and required combination therapy to eliminate bacteria.

Side effects

Drugs can interact with multiple targets while traveling to their intended target, which can cause side effects.

Difficulty finding the right target

It can be difficult to find the right target for a specific disease.

Difficulty delivering the drug

It can be difficult to deliver the drug in a stable form to the right target.

Poor solubility

Some drugs may have poor solubility, which can make it difficult to deliver them.

Difficulty crossing cellular barriers

Some drugs may have difficulty crossing cellular barriers, which can make it difficult to deliver them.

Rapid clearance from the body

Some drugs may be rapidly cleared from the body, which can make it difficult to deliver them.



CONCLUSION

Nanoparticle-based drug delivery systems (NDDS) represent a promising and transformative approach to treating chronic pulmonary diseases. By leveraging the unique properties of nanoparticles, such as their small size, high surface area, and ability to encapsulate a wide range of therapeutic agents, NDDS enable targeted and controlled drug release directly to the lungs. This targeted delivery minimizes side effects, improves bioavailability of drugs, and enhances therapeutic efficacy, particularly in diseases like chronic obstructive diseases.

In conclusion, nanoparticle-based drug delivery systems represent a groundbreaking solution for addressing chronic pulmonary diseases. Acting as targeted carriers, these "magic bullets" precisely deliver medications to affected lung regions, enhancing drug efficacy while minimizing collateral damage to healthy tissues. Their adaptability allows for personalized treatment, encapsulating various therapeutic agents for tailored patient care.

Their adaptability allows for personalized treatment, encapsulating various therapeutic agents for tailored patient care. Although promising, challenges like safety, scalability, and long-term effects necessitate further investigation and refinement. Despite these obstacles, the potential for improved treatment outcomes and reduced side effects signifies a transformative shift in managing chronic pulmonary diseases. Continued research and development in this area hold the key to unlocking the full therapeutic potential of nanoparticlebased drug delivery systems, potentially revolutionizing patient care in the future.

REFERENCE:

1. https://en.wikipedia.org/wiki/Nanoparticle_drug_delivery
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC3249419/
3. https://www.frontiersin.org/journals/molecularbiosciences/articles/10.3389/fmolb.2020.00193/ful
4. https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-018-0392-8
5. https://pmc.ncbi.nlm.nih.gov/articles/PMC9781272/
6. Abd-Rabou, A. A., and Ahmed, H. H. (2019). Bevacizumab and CCR2 inhibitornanoparticles induce cytotoxicity-mediated apoptosis in doxorubicin-treated hepaticand non-small lung cancer cells. Asian Pac. J. Cancer Prev. APJCP 20, 2225–2238.doi:10.31557/APJCP.2019.20.7.2225
7. Adali, M. B., Barresi, A. A., Boccardo, G., and Pisano, R. (2020). Spray freeze-drying asa solution to continuous manufacturing of pharmaceutical products in bulk. Processes 8,709. doi:10.3390/pr8060709
8. Ahmad, A. (2022). Pharmacological strategies and recent advancement in nano-drugdelivery for targeting asthma. Life 12, 596. doi:10.3390/life12040596
9. Akbarzadeh, I., Farid, M., Javidfar, M., Zabet, N., Shokoohian, B., Arki, M. K., et al.
10. (2022). The optimized formulation of tamoxifen-loaded niosomes efficiently inducedapoptosis and cell cycle arrest in breast cancer cells. AAPS PharmSciTech 23, 57–13.
    doi:10.1208/s12249-022-02212-0
11. Akhter, M. H., Rizwanullah, M., Ahmad, J., Ahsan, M. J., Mujtaba, M. A., and Amin, S. (2018).
12. Nanocarriers in advanced drug targeting: Setting novel paradigm in cancer therapeutics. Artif.cells, nanomedicine, Biotechnol. 46, 873–884. doi:10.1080/21691401.2017.1366333

13. Al-Otaibi, A. M., Al-Gebaly, A. S., Almeer, R., Albasher, G., Al-Qahtani, W. S., andAbdel Moneim, A. E. (2022). Potential of green-synthesized selenium nanoparticlesusing apigenin in human breast cancer MCF-7 cells. Environ. Sci. Pollut. Res. 29,
14. Alhawmdeh, M., Isreb, M., Aziz, A., Jacob, B. K., Anderson, D., and Najafzadeh, M. (2021). Interferon-γ liposome: A new system to improve drug delivery in the treatment of lung cancer. ERJ Open Res. 7, 00555. doi:10.1183/23120541.00555-2020
15. Almuqbil, R. M., Heyder, R. S., Bielski, E. R., Durymanov, M., Reineke, J. J., and Da Rocha, S. R. (2020). Dendrimer conjugation enhances tumor penetration and efficacy of doxorubicin in extracellular matrix-expressing 3D lung cancer models. Mol. Pharm. 17,1648–1662. doi:10.1021/acs.molpharmaceut.0c00083
16. Alphandéry, E. (2020). Iron oxide nanoparticles for therapeutic applications. DrugDiscov. Today 25, 141–149. doi:10.1016/j.drudis.2019.09.020
17. Alqahtani, J. S. (2022). Prevalence, incidence, morbidity and mortality rates of COPDin Saudi Arabia: Trends in burden of COPD from 1990 to 2019. PLoS One 17, e0268772.doi:10.1371/journal.pone.0268772
18. Sheersha Pramanik, Sourav Mohanto, Ravi Manne, Rahul R. Rajendran, A. Deepak, Sijo Joy Edapully, Triveni Patil, Oly Katari. Nanoparticle-Based Drug Delivery System: The Magic Bullet for the Treatment of Chronic Pulmonary Diseases. ACS publications. 2021. 18(10). 30-37
19. Biswajit Mukherjee, N.S.D., Ruma Maji, Priyanka Bhowmik, Pranab Jyoti Das and Paramita Paul. Current Status and Future Scope for Nanomaterials in Drug Delivery. National Library of Health. 2023. 10(8). 1609-1617.